| Identification | Back Directory | [Name]
Nicodicosapent | [CAS]
1269181-69-2 | [Synonyms]
Nicodicosapent
3-Pyridinecarboxamide, N-[2-[[(5Z,8Z,11Z,14Z,17Z)-1-oxo-5,8,11,14,17-eicosapentaen-1-yl]amino]ethyl]- | [Molecular Formula]
C28H39N3O2 | [MDL Number]
MFCD30747923 | [MOL File]
1269181-69-2.mol | [Molecular Weight]
449.63 |
| Chemical Properties | Back Directory | [Boiling point ]
677.5±55.0 °C(Predicted) | [density ]
1.013±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥ 100 mg/mL (222.41 mM); Ethanol: 2 mg/mL (4.45 mM); Water: < 0.1 mg/mL (insoluble) | [form ]
Solid | [pka]
13.26±0.46(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Nicodicosapent is a fatty acid niacin conjugate that is also an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1. | [in vivo]
Nicodicosapent (100 mg/kg po) produces high plasma levels of nicotinuric acid in the plasma. ApoE*3-Leiden mice treated with Nicodicosapent show a significant reduction in PCSK9 levels, LDL particles including VLDL and LDL cholesterol, as well as plasma triglycerides[1]. | [storage]
Store at -20°C | [References]
[1] Vu CB, et al. Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid. J Med Chem. 2016 Feb 11;59(3):1217-31. DOI:10.1021/acs.jmedchem.5b01961 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|